iA Global Asset Management Inc. Lowers Stock Holdings in Humana Inc. (NYSE:HUM)

iA Global Asset Management Inc. cut its stake in shares of Humana Inc. (NYSE:HUMFree Report) by 14.6% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 13,671 shares of the insurance provider’s stock after selling 2,344 shares during the period. iA Global Asset Management Inc.’s holdings in Humana were worth $4,330,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. PDT Partners LLC raised its stake in shares of Humana by 190.0% during the third quarter. PDT Partners LLC now owns 4,060 shares of the insurance provider’s stock worth $1,286,000 after purchasing an additional 2,660 shares during the last quarter. Ontario Teachers Pension Plan Board lifted its stake in shares of Humana by 6.5% in the 3rd quarter. Ontario Teachers Pension Plan Board now owns 1,173,535 shares of the insurance provider’s stock worth $371,705,000 after acquiring an additional 71,910 shares during the period. Swedbank AB boosted its holdings in shares of Humana by 3.0% in the third quarter. Swedbank AB now owns 105,976 shares of the insurance provider’s stock valued at $33,567,000 after acquiring an additional 3,085 shares in the last quarter. Heritage Oak Wealth Advisors LLC acquired a new position in shares of Humana during the second quarter worth about $3,456,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in Humana by 3.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 899,191 shares of the insurance provider’s stock worth $284,810,000 after purchasing an additional 26,056 shares in the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Humana Stock Down 0.5 %

Shares of NYSE HUM opened at $281.73 on Friday. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $33.92 billion, a PE ratio of 24.95, a P/E/G ratio of 2.27 and a beta of 0.53. The firm has a fifty day moving average of $272.68 and a 200-day moving average of $327.04. Humana Inc. has a 52-week low of $213.31 and a 52-week high of $488.89.

Humana (NYSE:HUMGet Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The firm had revenue of $29.30 billion during the quarter, compared to the consensus estimate of $28.66 billion. On average, analysts anticipate that Humana Inc. will post 16.14 EPS for the current year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.26%. The ex-dividend date is Tuesday, December 31st. Humana’s payout ratio is currently 31.36%.

Analyst Ratings Changes

Several equities analysts have issued reports on HUM shares. Cantor Fitzgerald reiterated a “neutral” rating and set a $395.00 target price on shares of Humana in a research report on Tuesday, October 1st. TD Cowen upped their price objective on Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a report on Monday, November 4th. Barclays raised their target price on Humana from $250.00 to $253.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. UBS Group lowered their price target on shares of Humana from $380.00 to $250.00 and set a “neutral” rating on the stock in a research note on Friday, October 4th. Finally, Sanford C. Bernstein upgraded shares of Humana from a “market perform” rating to an “outperform” rating and set a $308.00 price objective for the company in a research note on Tuesday, October 8th. Twenty analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $315.86.

Read Our Latest Stock Report on HUM

Humana Profile

(Free Report)

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Articles

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.